Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression

Journal of Hepatology

Volumn 58, Issue 1, 2013, Pages 73-80

  Memon, Khairuddin ^a   Kulik, Laura ^a   Lewandowski, Robert J ^a   Mulcahy, Mary F ^a   Benson, Al B ^a   Ganger, Daniel ^a   Riaz, Ahsun ^a   Gupta, Ramona ^a   Vouche, Michael ^a   Gates, Vanessa L ^a   Miller, Frank H ^a   Omary, Reed A ^a   Salem, Riad ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Liver function; Portal venous thrombosis; Progressive disease; Yttrium 90

Indexed keywords

SORAFENIB; TECHNETIUM 99M; YTTRIUM 90;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COHORT ANALYSIS; DIAGNOSTIC IMAGING; DISEASE COURSE; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RADIOEMBOLIZATION; SCORING SYSTEM; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DISEASE PROGRESSION; EMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATIENT SELECTION; PORTAL VEIN; VENOUS THROMBOSIS; YTTRIUM RADIOISOTOPES;

EID: 84871240780     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.09.003     Document Type: Article

References (27)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. F.X. Bosch, J. Ribes, M. Diaz, and R. Cleries Primary liver cancer: worldwide incidence and trends Gastroenterology 127 2004 S5 S16
3. J.F. Geschwind, R. Salem, B.I. Carr, M.C. Soulen, K.G. Thurston, and K.A. Goin Yttrium-90 microspheres for the treatment of hepatocellular carcinoma Gastroenterology 127 2004 S194 S205
4. R. Salem, R.J. Lewandowski, L. Kulik, E. Wang, A. Riaz, and R.K. Ryu Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma Gastroenterology 140 497-507 2011 e492
5. R. Salem, R.J. Lewandowski, M.F. Mulcahy, A. Riaz, R.K. Ryu, and S. Ibrahim Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology 138 2010 52 64
6. R.J. Lewandowski, L.M. Kulik, A. Riaz, S. Senthilnathan, M.F. Mulcahy, and R.K. Ryu A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization Am J Transplant 9 2009 1920 1928
7. A. Riaz, F.H. Miller, L.M. Kulik, P. Nikolaidis, V. Yaghmai, and R.J. Lewandowski Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma JAMA 303 2010 1062 1069
8. 90Y microspheres (TheraSphere): safety, tumor response, and survival J Vasc Interv Radiol 16 2005 1627 1639
9. B. Sangro, L. Carpanese, R. Cianni, R. Golfieri, D. Gasparini, and S. Ezziddin Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation Hepatology 54 2011 868 878
10. 90Y-resin microspheres for patients with advanced hepatocellular carcinoma Int J Radiat Oncol Biol Phys 66 2006 792 800
11. B.R. Davidson, M. Gibson, R. Dick, A. Burroughs, and K. Rolles Incidence, risk factors, management, and outcome of portal vein abnormalities at orthotopic liver transplantation Transplantation 57 1994 1174 1177
12. 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis Hepatology 47 2008 71 81
13. S. Senthilnathan, K. Memon, R.J. Lewandowski, L. Kulik, M.F. Mulcahy, and A. Riaz Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients Hepatology 55 2012 1432 1442
14. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
15. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
16. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, and A.X. Zhu Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
17. J.M. Llovet, and J. Bruix Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 2008 1312 1327
18. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
19. European Association for the Study of the L European Organisation for R Treatment of C EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
20. R. Salem, R.J. Lewandowski, V.L. Gates, C.W. Nutting, R. Murthy, and S.C. Rose Research reporting standards for radioembolization of hepatic malignancies J Vasc Interv Radiol 22 2011 265 278
21. 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations J Vasc Interv Radiol 17 2006 1251 1278
22. A. Forner, C. Ayuso, M. Varela, J. Rimola, A.J. Hessheimer, and C.R. de Lope Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115 2009 616 623
23. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
24. J. Bruix, M. Sherman, J.M. Llovet, M. Beaugrand, R. Lencioni, and A.K. Burroughs Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
25. A. Riaz, K. Memon, F.H. Miller, P. Nikolaidis, L.M. Kulik, and R.J. Lewandowski Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation J Hepatol 54 2011 695 704
26. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
27. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60